Since Alzheimer’s disease is progressive and changes in the brain can begin 10-20 years prior to symptom onset of cognitive decline, biofluid biomarkers are useful tools for monitoring the health of the brain over the lifetime of the patient. We still need biofluid biomarkers that track Alzheimer’s disease progression so that the disease can be detected early before cognitive decline.